On October 5th 2016, CM-Path invited industry representatives from pharmaceutical, molecular diagnostic and digital pathology companies to attend a workshop…
NCRI’s CM-Path initiative successfully launched
'The launch of NCRI’s Cellular Molecular Pathology initiative (CM-Path) took place on 6 June. Funders, NCRI Partners, consumers and CM-Path…
The CM-Path Initiative Launches
'On June 6th 2016, CM-Path members, funders and NCRI colleagues gathered in London for the intiative’s launch. » Download the…
The CM-Path launch set to take place on Monday 6th June
'On Monday 6th June, CM-Path members and funders will come together for the first time to set clear objectives and…
Interview with Dr Alex Freeman, member of NCRI’s CM-Path
'To mark International Clinical Trials Day this year we speak to Dr Alex Freeman, Consultant Histopathologist at University College London…
NCRI CM-Path Workstream Lead appointments and launch date
'CM-Path is NCRI’s newest initiative, which aims to reinvigorate pathology research in the UK. Following the appointment of the CM-Path…
Dr Karin Oien appointed Chair of NCRI’s new initiative in Cellular Molecular Pathology
'Following agreement of funding for the new NCRI Cellular Molecular Pathology (CM-Path) initiative and a recruitment call for key roles in the…
New funding for pathology is keeping cancer research at the cutting edge
'MORE THAN half a million pounds has been committed to a new initiative called Cellular Molecular Pathology (CM-Path) which aims…
CM-Path Cellular Pathology procedures with regards to release of research tissue samples (Word document)
'Cellular Pathology Departments act as a custodians of patient tissue samples held within diagnostic archives for NHS Trusts. Access, storage and archiving, must therefore be compliant with current good practice and legislative requirements.…
CM-Path SOP for Fresh Tissue Sampling (Word document)
'Molecular testing will become routine for many if not all pathology specimens in the future, as further genomic, transcriptomic, and proteomic changes present in disease can be harnessed for prognostication, therapeutic decision making, family screening, and prevention strategies. Accurate molecular testing is predicated upon well sampled, handled and preserved tissues, preferably fresh frozen. It is vital that fresh tissue sampling does not compromise the histological diagnosis and staging.…
CM-Path Recommendations for Molecular Testing and Research (Word document)
'The practice of molecular testing on pathological tissue samples is growing exponentially, but needs to be generalisable. The first step in this process is reducing variation introduced by processing of tissue from patient to Formalin Fixed Paraffin Embedded (FFPE) or Fresh Frozen (FF) sample. Low concordance rates of, for example, IHC are in part be due to variations in fixation media, time in fixation, processing protocols, and storage methods.…